


COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Currently amended claims showing deletions ~~by strikethrough~~ or [(double brackets)]
and additions by underlining)

1-8 (canceled)

9 (currently amended): A compound according to claim 1 of the formula (I),



(I)

the racemic-diastereomeric mixtures and optical isomers of said compound of formula (I) and pharmaceutically-acceptable salts thereof,

wherein

----- represents an optional bond;

R¹ is H;

R² is H;

R³ is -CH₂-indol-3-yl, -(CH₂)₄-NH-CO-O-t-Bu or -(CH₂)₄-NH₂;

R⁴ is H or -(CH₂)_m-A¹;

A¹ is -C(=Y)-N(X¹X²), -C(=Y)-X², -C(=NH)-X² or X²;

Y is O or S;

X¹ is H, (C₁-C₁₂)alkyl, -(CH₂)_m-NH-(C₁-C₆)alkyl, -(CH₂)_m-N-di-(C₁-C₆)alkyl or -(CH₂)_m-aryl;

X² is -(CH₂)_m-Y¹-X³ or optionally substituted (C₁-C₁₂)alkyl;


Y¹ is O, S, NH, C=O, (C₂-C₁₂)alkenyl having one or more double bonds,

-NH-CO-, -CO-NH-, -NH-CO-O-(CH₂)_m-, -C≡C-, SO₂ or a bond;


X³ is H, an optionally substituted moiety selected from the group consisting of (C₁-C₁₂)alkyl, (C₃-C₈)cycloalkyl, (C₁-C₁₂)alkoxy, aryloxy, (C₁-C₁₂)alkylamino, N,N-di-(C₁-C₁₂)alkylamino, -CH-di-(C₁-C₁₂)alkoxy, pyrrolidinyl, pyridinyl, thiophene, imidazolyl,

Inventor : Thurieau *et al.*
Serial No. : 10/771,725
Filed : February 4, 2004
Page : 6

piperidinyl, piperazinyl, benzothiazolyl, furanyl, indolyl, morpholino, benzo[b]furanyl,
quinolinyl, isoquinolinyl, -(CH₂)_m-phenyl, naphthyl, fluorenyl, phthalamidyl,
pyrimidinyl,



or X^1 and X^2 are taken together with the nitrogen to which they are attached to form an optionally substituted moiety selected from the group consisting of thiazolyl




Y^2 is $CH-X^4$, $N-X^4$, $-C(X^4X^4)$, O or S;

X^4 for each occurrence is independently $-(CH_2)_m-Y^3-X^5$;

Y^3 is $-C(O)-$, $-C(O)O-$ or a bond;

X^5 is hydroxy, (C_1-C_{12}) alkyl, amino, (C_1-C_{12}) alkylamino, N,N -di- (C_1-C_{12}) alkylamino, or an optionally substituted moiety selected from the group consisting of aryl, aryl (C_1-C_4) alkyl, furanyl, pyridinyl, indolyl, $-CH(phenyl)_2$,



where m for each occurrence is independently 0 or an integer from 1 to 6;

R^5 is phenyl, o-methoxyphenyl, p-Br-phenyl, p-nitro-phenyl or p- N,N -diethylamino-phenyl;

R^6 is H.

10 (canceled)

11 (original): A compound according to claim 9 wherein R^5 is phenyl and R^3 is $-(CH_2)$ -indol-3-yl and the stereochemistry at the carbon to which R^3 is attached is the R-configuration.

12-29 (canceled)

30 (withdrawn – currently amended): A pharmaceutical composition comprising a compound according to claim [[1]] 9 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

31-33 (canceled)

34 (withdrawn – currently amended): A method of treating acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves' Disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, cancer, cancer cachexia, hypertension, postprandial

Inventor : Thurieau *et al.*
Serial No. : 10/771,725
Filed : February 4, 2004
Page : 8

hypotension, panic attacks, GH secreting adenomas or TSH secreting adenomas, in a subject in need thereof, which comprises administering a compound according to claim [[1]] 9 or a pharmaceutically acceptable salt thereof to said subject.

35 (withdrawn – currently amended): A method of treating diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X, angiopathy, proliferative retinopathy, dawn phenomenon, **Nephropathy**, peptic ulcers, enterocutaneous and pancreaticocutaneous fistula, Dumping syndrome, watery diarrhea syndrome, acute or chronic pancreatitis, gastrointestinal hormone secreting tumors, ~~angiogenesis, inflammatory disorders~~, chronic allograft rejection, ~~angioplasty~~, graft vessel bleeding or gastrointestinal bleeding in a subject in need thereof, which comprises administering a compound according to claim [[1]] 9 or a pharmaceutically acceptable salt thereof to said subject.

36-43 (canceled)